Voices
Al-Ola Abdallah: Comparing Daratumumab Regimens in Older Patients With RRMM
Al-Ola Abdallah/LinkedIn

Al-Ola Abdallah: Comparing Daratumumab Regimens in Older Patients With RRMM

Al-Ola Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared a post on LinkedIn:

“Comparative Efficacy of Daratumumab Based Regimens in Patients With Relapsed-Refractory Multiple Myeloma (RRMM) Aged 70 and Above: A Multicenter Study.”

Title: Comparative Efficacy of Daratumumab Based Regimens in Patients With Relapsed-Refractory Multiple Myeloma (RRMM) Aged 70 and Above: A Multicenter Study

Authors: Razan Mansour, Kimberly M. Green, Chandler Graf, Mark Chang, Gray Magee, James A. Davis, Anas Zayad, Nausheen Ahmed, Muhammad Umair Mushtaq, Evguenia Ouchveridze, Zahra Mahmoudjafari, Barry Paul, Nicole Twardowski, Shebli Atrash, Al-Ola Abdallah

Read the Full Article.

Al-Ola Abdallah: Comparing Daratumumab Regimens in Older Patients With RRMM

More posts featuring Al-Ola Abdallah.

Al-Ola Abdallah Anas Zayad Barry Paul cancer Chandler Graf Evguenia Ouchveridze Gray Magee James A. Davis Kimberly M. Green Mark Chang Muhammad Umair Mushtaq multiple myeloma Nausheen Ahmed Nicole Twardowski OncoDaily Oncology Razan Mansour RRMM Shebli Atrash Zahra Mahmoudjafari